A collaborative study was conducted for determination of glucosamine in raw materials and dietary supplements containing glucosamine sulfate and/or glucosamine hydrochloride by high-performance liquid chromatography (HPLC) with N-(9-fluorenyl-methoxycarbonyloxy) succinimide (FMOC-Su) derivatization. Thirteen blind materials, one pair of which were duplicates, were tested by 12 collaborating laboratories. The test samples consisted of various commercial products, including tablets, capsules, drink mix, and liquids as well as raw materials, blanks, and those for spike recovery analyses. The tests with blank products and products spiked with glucosamine showed good specificity of the method. The average recoveries at spike levels of 100 and 150% of the declared amount were 99.0% with a relative standard deviation (RSD) of 2.1%, and 101% with an RSD of 2.3%, respectively. The test results between laboratories on each commercial product were reproducible with RSD values of no more than 4.0%, and the results were repeatable in the same laboratory with an average RSD of 0.7%. HorRat values ranged from 0.5 to 1.7 on both tests of spike recovery and reproducibility between laboratories on commercial products. The average determination coefficient of the calibration curves from the laboratories was 0.9995 with an RSD of 0.03%. All of the 12 collaborating laboratories succeeded in the study and none of their reported test results were outliers, partly indicating the robustness of the method. It is recommended that the method be accepted by AOAC INTERNATIONAL as Official First Action.
T he glucosamine high-per for mance liq uid chro ma tog ra phy (HPLC) method with N-(9-fluorenylmethoxycarbonyloxy) succinimide (FMOC-Su) derivatization (1-3) was se lected by an AOAC ex pert re view panel (ERP) as the most ap pro pri ate method to rec om mend for fur ther lab o ra tory val i da tion. The re sults of the sub se quent sin gle lab o ra tory val i da tion (SLV) study, when sub jected to peer re view by the ERP and se lected mem bers of the AOAC INTERNATIONAL Meth ods Com mit tee on Di etary Sup ple ments, in di cated the method was suit able for a full collaborative study (4) .
The col lab o ra tive study was con ducted to eval u ate the method ac cu racy and pre ci sion based on its intra-and interlaboratory per for mance (5, 6) . In this study, 13 glucosamine test ma te ri als, in clud ing a pair of blind du pli cates, were an a lyzed by 12 col lab o rat ing lab o ra to ries. These ma te ri als con sisted of var i ous com mer cial prod ucts as well as blanks and spike recovery samples.
Glucosamine prod uct is one of the most pop u lar di etary sup ple ments in the United States, and its ef fec tive ness has been clin i cally proven for the treat ment of osteoarthritis (7) . Glucosamine hydrochloride (HCl) and glucosamine sul fate are the 2 most im por tant glucosamine salt forms used in these prod ucts and claimed on the prod uct la bels. The es tab lish ment of an of fi cial glucosamine method will fa cil i tate the qual ity con trol and regulatory compliance of the product.
Collaborative Study

Study Design
The study was con ducted on 12 dif fer ent test ma te ri als. One of them was split into 2 iden ti cal sam ples to test re peat abil ity of the an a lyt i cal re sults in the same lab o ra tory. The iden tity or con tent of these 13 test sam ples was not re leased to the col lab o ra tors, and ran dom iden ti fi ca tion num bers were as signed to each of the test ma te ri als. A set of these ma te ri als and the glucosamine ref er ence stan dard were sup plied to each of the lab o ra to ries for the study. Prac tice sam ples were also pro vided to en sure that par tic i pants could suc cess fully fol low the method and op ti mize their in stru ments be fore pro ceed ing with the ac tual tests. The Study Di rec tor was avail able for con sul ta tion. Ta ble 1 lists the 13 test samples and their ingredients and potencies.
Collaborators
Twelve lab o ra to ries par tic i pated in the study. Three were in dus trial man u fac tur ers of di etary sup ple ment fin ished prod ucts, 5 were raw ma te rial ven dors, 3 were com mer cial test ing lab o ra to ries, and one was the uni ver sity lab o ra tory. Geo graph i cally, 10 laboratories were from the United States, one from Canada, and one from Germany.
Study Procedures
Prod uct types.-Ba si cally, 5 types of test ma te ri als were an a lyzed: (1) tab lets, (2) cap sules, (3) drink mix pow der, (4) raw ma te ri als, and (5) liq uid prod ucts. At least one prod uct of each type was cho sen to rep re sent the group. These rep re sen ta tive sam ples also cov ered dif fer ent ma te rial sources, e.g., glucosamine from shell fish or glucosamine from veg e ta ble source; dif fer ent salt forms: glucosamine HCl and glucosamine sul fate; and dif fer ent com bi na tion prod ucts with 
Sam ple po tency range.-Be cause of the large va ri ety of test ma te ri als cov ered in this study, the glucosamine con cen tra tions dif fered greatly in these sam ples. As shown in Ta ble 1, for ex am ple, with the same quan tity but dif fer ent type of sam ples, 12.6 g com mer cial drink mix pow der (G6) con tains only 1.5 g glucosamine HCl. How ever 12.6 g glucosamine HCl raw ma te rial (G4) con tains 12.4 g glucosamine HCl. In ad di tion, be tween dif fer ent types of glucosamine salt forms, i.e., glucosamine sul fate and glucosamine HCl, 1 g glucosamine sul fate in dus trial raw ma te rial (G3) con tains only 0.59 g glucosamine free base (GFB); the ma te rial has the com plex em pir i cal for mula 2GFB·H 2 SO 4 ·2KCl, but 1 g glucosamine HCl (G4) con tains 0.83 g GFB. These dif fer ences make it dif fi cult to use the same test portion size in weight for all the products in the method. There fore, to en sure the best ac cu racy of tests, the method has classified different product categories for sampling.
Prep a ra tion of test sam ples.-(1) Com mer cial prod ucts.-All products were re moved from their orig i nal com mer cial pack ages to con ceal the man u fac turer's in for ma tion. Tab lets were ground into pow der, but cap sules were kept un changed (be cause con tents once emp tied from the shells are ready to pro ceed for anal y sis). The pow ders in clud ing raw ma te ri als and drink mix were well mixed to pre vent non-uni for mity prob lems. For ship ment, 20-30 g pow der or 60 cap sules were packed into a film bag. The liq uid prod ucts were mixed thor oughly and repacked into 60 mL plastic bottles for shipment.
(2) Blank pow der.-A com bi na tion blank pow der for tab lets and cap sules was pre pared based on the weight per cent ages shown in Ta ble 1 and treated as a tab let pow der for analysis.
(3) Spike re cov ery sam ples.-The 2 products for spike re cov ery lev els I and II were ini tially made as a liq uid us ing the blank pow der and glucosamine ref er ence stan dard to avoid ho mo ge ne ity prob lems, but those prod ucts de com posed from mi cro bial ac tion. It was later found that 1% so dium ben zo ate can be used as a pre ser va tive. Be cause of time lim i ta tion and sta bil ity con cerns on the other prod ucts, the col lab o ra tors were asked to pre pare G1 and G2 (the 2 spike re cov ery sam ples) with the glucosamine HCl stan dard and G12 (the blank pow der) pro vided. But the iden tity of G1 and G2 and con tent of G12 (marked as a tab let pow der) were kept un known to col lab o ra tors. G1 and G2 were prepared by ac cu rately mix ing 360 ± 10 mg glucosamine HCl stan dard with 70 ± 10 mg G12 (spike re cov ery level I 150%), and mix ing 240 ± 10 mg glucosamine HCl stan dard with 190 ± 10 mg G12 (spike re cov ery level II 100%), re spec tively. The base for the above spike per cent age lev els is 240 mg glucosamine HCl. This amount dis solved in the sol vent in a 100 mL flask is the ex pected con cen tra tion de signed for this method to an a lyze var i ous glucosamine products (see Prep a ra tion of Test So lu tions in the method).
All of the above test sam ples were pro cessed un der clean and con trolled con di tion to avoid con tam i na tion. Glucosamine in solid state is, in gen eral, chem i cally sta ble, but un der spe cial cases such as hot tem per a ture and chem i cal re ac tions as well as mi cro bial ac tion, it may degrade.
Ship ment.-Test sam ples and stan dard were shipped to col lab o ra tors at am bi ent tem per a ture. Each of the test bags or bot tles was la beled for iden ti fi ca tion (e.g., G1, G2, and prod uct type, e.g., tab let pow der) to as sist col lab o ra tors in dif fer en ti at ing the prod ucts and find ing the right cat e go ries. Col lab o ra tors were re quired to re turn a re ceipt ac knowl edge ment form to in di cate re ceipt and con di tion of the shipped items. They were also di rected to store products and standard at room temperature.
Prac tice sam ples.-The prac tice sam ples were pre pared, ran domly coded (e.g., P1, P2), shipped, and an a lyzed as if they were the ac tual sam ples. Col lab o ra tors were re quired to an a lyze the practice sam ples and re port the re sults to ob tain the Study Di rec tor's ap proval be fore pro ceed ing with the actual study.
Anal y sis.-Col lab o ra tors were re quired to pre pare new cal i bra tion so lu tions and curve each test day. For test ma te rial anal y sis, sin gle prep a ra tion and sin gle in jec tion were required.
Data re port ing.-Col lab o ra tors were asked to re port the lin ear ity of each cal i bra tion curve, the cor re spond ing con cen tra tions of the cal i bra tion so lu tions, and the per cent ages of GFB found in each of the 13 test sam ples on the data re port ing sheets. They were also asked to re port any ob ser va tions and deviations to the method.
Ex pected val ues and val i da tion data of the test ma te ri als.-Ta ble 2 lists the ex pected val ues (e.g., the GFB val ues cal cu lated from the la bel claims) and val i da tion data of the test ma te ri als. The val i da tion data were ob tained by the Study Di rec tor's lab o ra tory at NOW Foods (Bloomingdale, IL) us ing the same method and on the same ma te ri als as sent to the col lab o rat ing laboratoies in this study. (Ap pli ca ble to the anal y sis of glucosamine in raw ma te ri als and di etary sup ple ments con tain ing glucosamine sul fate and/or glucosamine hy dro chlo ride.)
AOAC
See Tables 2005.01A and B for the results of the interlaboratory study supporting acceptance of the method.
A. Prin ci ple
Glucosamine sul fate/hy dro chlo ride fin ished prod ucts or raw ma te ri als are dis solved in wa ter. The glucosamine free base (GFB) is re leased by add ing triethylamine to the so lu tion and derivatized with N-9-fluorenylmethoxycarbonyloxy succinimide (FMOC-Su). The de riv a tive is sep a rated by high-per for mance liq uid chro ma tog ra phy (HPLC) and mea sured with UV de tec tion. Glucosamine has 2 nat u ral steroisomers (a and b), and the interconversion of these 2 in aque ous so lu tion is not pre vent able, re sult ing in 2 peaks in the chromatogram. The sum of the ar eas of these 2 peaks is used to quantify the GFB. a SD r = Reproducibility standard deviation; %RSD R = reproductibility relative standard deviation; %PRSD R = predicted reproducibility relative standard deviation.
B. Ap pa ra tus
Note: Equiv a lent ap pa ra tus may be sub sti tuted. All glass ware is Class A.
(a) LC sys tem.-Agilent HPLC 1100 se ries with pump, degasser, autosampler, thermostatted col umn com part ment, vari able wave length de tec tor, and Chemstation soft ware for sys tem con trol and data ac qui si tion (Agilent Tech nol o gies, Inc., Palo Alto, CA; www.agilent.com). Op er ate the LC sys tem un der the fol low ing con di tions: mo bile phase flow rate, 0.8 mL/min; de tec tion wave length, 265 nm; col umn com part ment tem per a ture, 30°C; and in jec tion vol ume, 10 mL. 
C. Re agents
Note: Chem i cals from other sup pli ers meet ing the spec i fi ca tions may also be used.
( tab lets, find and re cord the mean weight of 20 tab lets, grind, mix, and weigh. For cap sules, empty and re cord the mean fill weight of 20 cap sules, grind the con tents, mix, and weigh. For liq uid prod ucts, shake well be fore tak ing the test portion.
Add ca 80 mL wa ter to the test por tion, mix on a Vor tex mixer for 1 min, and sonicate for 5 min or un til all sol ids dis solve. (Note: Some of the prod ucts' ex cipi ents, e.g., sil i con di ox ide, may never dis solve.) Pipet 750 mL TEA into each of the flasks and di lute to vol ume with wa ter. Fil ter ca 1.5 mL of each so lu tion through a 0.45 mm ´ 25 mm PTFE fil ter into an LC injection vial.
E. Derivatization Pro ce dures
Note: Both stan dards and test so lu tions must be derivatized si mul ta neously in 5 mL vol u met ric flasks.
Pipet the ex act amount, as spec i fied be low, of the fil tered so lu tions from the LC in jec tion vi als into sep a rate 5 mL vol u met ric flasks: glucosamine stan dard work ing so lu tions (3-point cal i bra tion): 50, 125, and 200 mL, re spec tively; and for all other prod ucts: 125 mL. Add 500 mL 15mM FMOC-Su so lu tion to each flask. Cap flasks tightly with Tef lon stop pers, mix well with a Vor tex mixer, and sonicate all flasks in the sonicator wa ter bath at 50°C for 30 min. Re move the flasks from the bath, let cool to room tem per a ture, and di lute to vol ume with the mix ture of mo bile phases A/B (1/1, v/v). Mix well with a Vor tex mixer. Fil ter each so lu tion through 0.45 mm ´ 13 mm PTFE filter into an LC vial for injection.
F. De ter mi na tion
(a) Sys tem suit abil ity tests.-Equilibrate the LC sys tem with the mo bile phase for at least 30 min. Make 5 rep li cate in jec tions of the sec ond (mid-con cen tra tion) glucosamine HCl work ing stan dard. The typ i cal re ten tion time (t) of glucosamine anomer peak 1 (the ear lier eluted peak) should not be <4 min, and the rel a tive re ten tion time (R r ) of glucosamine anomers peaks 2 to 1 should be 1.2 (R r = t 2 /t 1 ). The peak tail ing fac tor (T) should not be >2.0 (T = W 0.05 /2f, where W 0.05 is width of the peak mea sured at a point 5% of the peak height from the base line; and f is hor i zon tal dis tance from the ver ti cal line at the peak max i mum to the point on lead ing edge of the peak at 5% height. The rel a tive stan dard de vi a tion (RSD) of the sums of peak area of glucosamine peaks 1 and 2 from the 5 injections should not be >2.0%. 
G. Cal cu la tions
(a) Con cen tra tions of glucosamine work ing stan dard so lu tions.-Cal cu late the con cen tra tions of GFB in work ing stan dard so lu tions, af ter FMOC derivatization:
STD n, mg/mL = 0.83091 ´ d ´ W ´ F where n = 1, 2, 3 for 3 dif fer ent stan dard work ing so lu tions; 0.83091 is the con ver sion fac tor from glucosamine HCl to GFB: 179.17/215.63; d = the di lu tion fac tor: v/(100 mL 5 mL), with v = 0.050, 0.125, and 0.200 mL for STD1, STD2, STD3, re spec tively; W = the amount of glucosamine HCl stan dard weighed, mg; and F = the pu rity fac tor of glucosamine HCl standard used.
(b) Per cent age of GFB in all glucosamine con tained ma te ri als.-Cal cu late the % GFB in all glucosamine-con tained ma te ri als:
where P = the sum of peak area of glucosamine peaks 1 and 2 of the un known test sam ple; a = slope of the cal i bra tion curve; b = in ter cept of the cal i bra tion curve; D is the di lu tion fac tor: v/(100 mL ´ 5 mL), with v = 0.125 mL; W = the amount of test por tion weighed, mg.
For liq uids:
where V = the amount of test portion volume used, mL. 
Results and Discussion
Collaborative Study Results
The anal y ses were com pleted by all 12 col lab o rat ing lab o ra to ries in 2 weeks. The sam ple iden ti fi ca tion, which was ran domly as signed to the test sam ples, was de coded af ter the test re sults were re ceived, and the names of the par tic i pat ing lab o ra to ries were coded from L1 to L12 for their data presentation in this report.
Ta ble 3 shows the com plete set of data sub mit ted from the col lab o rat ing lab o ra to ries in the per cent ages of GFB for a ND = None detected. b G13 and G10 were 2 identical samples. However, the collaborators were not informed they were the blind duplicates. 8 com mer cial prod ucts and 2 dif fer ent blanks. These data in di cate the method per for mance on reproducibility of the an a lyt i cal re sults be tween lab o ra to ries. Ta ble 3 also shows the re sults on 2 iden ti cal test sam ples (G10 and G13) that in di cate the method per for mance on the re peat abil ity of the an a lyt i cal re sults in the same laboratory and reproducibility be tween lab o ra to ries. Ta ble 4 shows the con cen tra tions of cal i bra tion so lu tions and lin ear ity of cal i bra tion curves re ported from each lab o ra tory. Ta ble 5 shows the re cov ery re sults of 2 spike lev els from all the lab o ra to ries. The per cent ages of spike re cov ery were cal cu lated by di vid ing the per cent GFB found in each test sam ple by the per cent GFB for ti fied in the test sam ple and mul ti ply ing by 100. The data indicate both the method accuracy and method precision between laboratories. The re sults in Ta ble 3 were used to gen er ate the sta tis ti cal data pre sented in Ta bles 2005.01A and B, re spec tively, for reproducibility be tween lab o ra to ries and re peat abil ity in the same laboratory.
Av er age (A), stan dard de vi a tion (SD), and rel a tive stan dard de vi a tion (RSD) used for the sta tis ti cal anal y sis are de fined as follows:
where A i is the in di vid ual mea sure ment on the sam ple; and N is the num ber of data points needed to achieve 3A i .
The HorRat value is the ra tio of the RSD, ex pressed as a per cent (%RSD) to the pre dicted RSD, ex pressed as a per cent (%PRSD), i.e., HorRat = %RSD / %PRSD, where %PRSD = 2C -0.1505 and C = the mea sured mean con cen tra tion of the analyte ex pressed as a dec i mal mass frac tion (e.g., 1 g/100 g = 0.01). For the spike re cov ery re sults pre sented in Ta ble 5, the true con cen tra tions of GFB (%GFB spiked/100) was used to cal cu late %PRSD for HorRat val ues. For the sta tis ti cal data shown in Ta bles 2005.01A and B, the ex per i men tal con cen tra tion val ues of %GFB/100 were used to calculate %PRSD. Fig ure 1 shows sam ple chromatograms from Lab o ra tory 2 (L2) of glucosamine stan dard sam ple 3, com mer cial glucosamine sul fate tab lets (G10), and blank pow der combination ma trix for tab lets and capsules (G12).
Col lab o ra tors' Com ments
Most col lab o ra tors found the method easy to fol low and per form. Rea son able mod i fi ca tions of the method (as shown be low) with out sig nif i cantly af fect ing the test re sults and with the Study Di rec tor's per mis sion were al lowed to show the method robustness.
Lab o ra tory 2 in creased the post-gra di ent equil i bra tion time from 2 to 7 min be fore next in jec tion for a to tal run time of 20 min. The re sults from the other lab o ra to ries were ob tained by us ing the con di tions per the method.
Lab o ra tory 5 ob served a small peak around a re ten tion time of 4.1 min when the an a lyst used wa ter as a blank for test. The lab o ra tory also ob served this lit tle peak in some glucosamine sam ple anal y sis, and sus pected it had merged with peak 1 of glucosamine in other tests. The an a lyst also found in some tests an other small peak be tween peaks 1 and 2 of glucosamine. It is not sure that the peaks were due to some im pu ri ties in the par tic u lar lot of the re agents. How ever, be cause these peaks were very small, the quantitation re sults from the lab o ra tory were not affected (Tables 3-5 Lab o ra tory 6 re ported that dur ing a rep li cate in jec tion of 5, the area of glucosamine peak 1 slightly in creased while the area of peak 2 slightly de creased, but the to tal area of peaks 1 and 2 re mained the same (RSD = 0.19 and 0.33%, with 5 in jec tions for each of 2 trials). Lab o ra tory 7 an a lyzed the test sam ples af ter they were pre pared and stored in LC vi als for 4 days at am bi ent tem per a ture. The re sults are ad e quate, in di cat ing good sta bil ity of the glucosamine-FMOC-Su derivatives.
Lab o ra tory 10 pre pared all the materials by us ing half of the rec om mended amount for sam pling, and 50 mL in stead of the 100 mL vol u met ric flasks per the method. For derivatization, Laboratory 10 used 10 mL in stead of 5 mL vol u met ric flasks, and all rec om mended vol umes for test solution and re agents were dou bled. Some of the dif fer ences in test portion weight were shown in Ta ble 4 (amounts of the blank pow der and glucosamine HCl stan dard used). How ever, all of their test results are acceptable.
Lab o ra tory 11 per formed the tests with out a guard col umn. Lab o ra tory 12 no ticed in sol u ble res i dues in the sam ple prep a ra tions of G1, G2, G8, G10, G12, and G13.
None of the col lab o rat ing lab o ra to ries re ported any sys tem suit abil ity prob lems in the study.
Performance Characteristic of the Method
In sum ma ries of the data (Ta bles 3-5 and 2005.01A and B) the tests with the blank materials and the products with glucosamine spiked showed good spec i fic ity of the method. Spec i fic ity can be de fined as the abil ity to mea sure ac cu rately the con cen tra tion of an analyte in the pres ence of all other ma te ri als (4, 6) . As shown in Ta ble 3, the 2 blank ma trixes (G11 and G12) con tain ing SAMe, vi ta min A, cit ric acid, chondroitin sul fates, MSM, lemon juice con cen trate, and other in gre di ents had none de tected re ported from all lab o ra to ries at the re ten tion times cor re spond ing to glucosamine peaks, in di cat ing no in ter fer ence to glucosamine quantitation. The spike re cov ery study also bore ev i dence that the method is ac cu rate. The av er age spike re cov er ies pre sented in Ta ble 5 at the spike lev els of 100 and 150% were 99.0% with an RSD of 2.1%, and 101% with an RSD of 2.3%, re spec tively. The test re sults be tween lab o ra to ries on each com mer cial prod uct were re pro duc ible with all RSD val ues of no more than 4.0%. The re sults were re peat able in the same lab o ra tory on 2 iden ti cal sam ples, with an av er age RSD of 0.68% for all lab o ra to ries. The av er age de ter mi na tion coefficient of the calibration curves from the laboratories was 0.9995 with an RSD of 0.03%.
HorRat val ues showed 0.9 and 1.1 for the spike re cov ery anal y sis at the lev els of 100 and 150%, re spec tively. For the tests of reproducibility be tween lab o ra to ries on each com mer cial prod uct, HorRat val ues ranged from 0.5 to 1.7.
The tests of re peat abil ity in the same lab o ra tory on 2 blind du pli cates showed HorRat val ues of 0-0.6 for all lab o ra to ries. The zero and near zero val ues for HorRat are the re sults of some lab o ra to ries find ing and re port ing the ex actly same or sim i lar %GFB on 2 iden ti cal tab let sam ples (G10 and G13), which di min ished the RSD in the nu mer a tor for cal cu la tion of the HorRat value. The fact that col lab o rat ing lab o ra to ries found the same or very sim i lar re sults on 2 blind du pli cates among 13 test materials demonstrated well the reliability of the method.
The method is also rug ged and ro bust (see refs 6 and 8 for def i ni tions). The method has been tested by 12 col lab o rat ing lab o ra to ries on var i ous test ma te ri als. Al though the same method was fol lowed, the ac tual use con di tions in dif fer ent lab o ra to ries may vary greatly with dif fer ent equip ment brand, qual ity, and per son nel. For ex am ple, the wa ter bath may dis play ex actly 50°C, but the real tem per a ture could be 55°C (or more or less) if the tem per a ture sen sor was not cal i brated, or the reg u la tor on the bath did not work so well (ac cu rately); or, if some lab o ra tory sim ply ac cepted 55°C in stead of 50°C as re quired, but did not re port the dif fer ence to the Study Di rec tor, and so on. It is im por tant to note that all 12 col lab o rat ing lab o ra to ries suc ceeded in the study and none of their re ported test results were outliers, partly indicating the robustness of the method.
Be cause glucosamine con cen tra tion in com mer cial prod ucts changes sig nif i cantly with prod uct man u fac turer, type (tab lets, cap sules, raw ma te ri als, etc.), and glucosamine salt form used (glucosamine hy dro chlo ride and glucosamine sul fate), the tests may be more ac cu rate if the sam pling amount is based on its label claims.
Rec om men da tions
Based upon the re sults of the col lab o ra tive study, it is rec om mended that the method be ac cepted by AOAC IN TER NA TIONAL as Of fi cial First Action.
